Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Helicobacter System And Uses Thereof

a technology of helicobacter and plasmid, applied in the field of helicobacter-based vectors, plasmid vectors and shuttle vector systems, can solve the problems of poor immunogenicity of antigens delivered, unable to find application in mucosal delivery systems, and hindering the development of mucosal vaccines

Active Publication Date: 2007-06-14
ONDEK
View PDF63 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0039] Nucleotide sequence of H. pylori insertion construct, HopE gene with nucleotide sequence of interest, “X”. (580 bp HopE—“X” bp—502 bp HopE). The nucleotide sequence of interest, “X”, may comprise a nucleic acid sequence that encodes a molecule of interest, such as a biologically valuable molecule of interest. A biologically valuable molecule of interest may comprise an enzyme, protein, peptide, or other molecule that is capable of providing a beneficial or therapeutic effect to an animal as delivered as an expressed product though or at a mucosal surface, such as the gastric mucosa. In some embodiments, “X” is a nucleic acid sequence comprising 60 nucleotide bases to 150 nucleotide bases, or 69 nucleotide bases to 138 nucleotide bases.

Problems solved by technology

However, this particular application has not found application in mucosal delivery systems in part owing to its involvement in a variety of diseases.
The development of mucosal vaccines has also been hindered by the poor immunogenicity of antigens delivered by conventional approaches because of natural barrier functions of the host that prevent access to the mucosal compartment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Helicobacter System And Uses Thereof
  • Helicobacter System And Uses Thereof
  • Helicobacter System And Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Vectors and Transgenic H. pylori Organisms for Stable Expression of Foreign Proteins

[0154] The genetic manipulation of H. pylori is uncommon. The present example demonstrates the utility of the invention for providing a genetically transformed Helicobacter, particularly transformed H. pylori. The transformed bacterium are prepared using plasmids and plasmid vectors derived from Helicobacter, which have had been subject to prior manipulation in a non-Helicobacter organism, such as E. coli.

[0155] Several H. pylori plasmids described in the literature can be successfully converted to H. pylori / E. coli shuttle vectors. Many strains of E. coli have been reported to be naturally competent for DNA uptake. Resistance markers for streptomycin, rifampin and metronidazole have also been successfully transformed into most strains of H. pylori. However, while plasmid DNA from E. coli and other organisms can be introduced into H. pylori, these plasmids cannot be stably maintained. Moreover, H. ...

example 2

Expression Vectors and Selection of Antigens for Stable Expression

[0167] Because HopE is a native protein of H. pylori, it is tolerated by this organism and can thus form a construct useful for expressing foreign antigens or other heterologous gene products in H. pylori. Other H. pylori / E. coli shuttle vectors that can be readily developed as described above include, for example, vectors comprising two plasmid ori sites and markers which are suitable for each host. Markers might include genes for chloramphenicol / kanamycin resistance as well as promoters that can be recognized by both the E. coli and H. pylori transcriptional systems.

[0168] The requirements for replication E. coli can be achieved by using any of a number of known E. coli plasmids (e.g., pBR322).

[0169] Constructed shuttle vectors can be tested for replication in both E. coli and H. pylori in vitro and compared to existing shuttle plasmids described in the literature.

[0170] The choice of antigen or other heterologo...

example 3

Virulence, LD50

[0179] As described in Examples 1 and 2, Helicobacter-based vectors such as pHP3 and pHP623 are capable of providing protection against infection in a mammal, such as a mouse or human. In the present example, a murine model is used to demonstrate the utility of using the Helicobacter-based systems to provide delivery of a pharmacologically active molecule of interest to a mammal, including a human. The murine model is employed to demonstrate the activity of a transgenic strain of H. pylori to elicit a serological response to an expressed surface antigen in vivo.

[0180] Mice are infected with wild-type H. pylori, while other mice are inoculated by gavage with temperature-sensitive H. pylori as described in Example 2. Sera from both control and test animals are assayed for antibody and gastric histology are performed on sacrificed animals in accordance with the schedule shown in Table 1. A mouse urea breath test can also be used.

[0181] A 50% decrease in virulence (fro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and / or vaccination against disease are provided. Delivery of the pharamacologically active molecules is provided at the mucosal surface, such as the gastric mucosa or nasal membranes, to provide effective and continuous delivery of a pharmacologically active agent. In some embodiments, the Helicobacter provides exposure of a desired molecule of interest though the surface of the Helicobacter, providing exposure of the antigen to the host at the gastric mucosa. Live Helicobacter pylori vaccines are also provided. Vectors and shuttle vector constructs of the Helicobacter are also disclosed.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 60 / 602,859, filed Aug. 20, 2004, and to Australian Patent Application No. 2004 / 904564, filed Aug. 13, 2004, and to U.S. Utility application Ser. No. 11 / 202,249, filed Aug. 12, 2005, the text of all applications being specifically incorporated herein by reference.BACKGROUND [0002] 1. Field of the Invention [0003] The present invention relates generally to the field of Helicobacter-based vector, plasmid vector and shuttle vector systems, as novel Helicobacter constructs that include a non-Helicobacter pharmacologically active molecule of interest are provided. The invention also relates to the field of drug delivery, vaccines and treatment methods, as compositions that provide for the administration and / or delivery of non-Helicobacter molecules at the mucosa in vivo are disclosed. [0004] 2. Related Art [0005]Helicobacter pylori are a gram-negative spiral shaped bacter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/02C12N1/21
CPCA61K39/00A61K48/0008C07K14/205A61K2039/542A61K2039/523A61P37/04
Inventor MARSHALL
Owner ONDEK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com